ID   KMT2C_HUMAN             Reviewed;        4911 AA.
AC   Q8NEZ4; Q8NC02; Q8NDF6; Q9H9P4; Q9NR13; Q9P222; Q9UDR7;
DT   10-OCT-2003, integrated into UniProtKB/Swiss-Prot.
DT   20-JAN-2009, sequence version 3.
DT   12-APR-2017, entry version 159.
DE   RecName: Full=Histone-lysine N-methyltransferase 2C;
DE            Short=Lysine N-methyltransferase 2C;
DE            EC=2.1.1.43;
DE   AltName: Full=Homologous to ALR protein;
DE   AltName: Full=Myeloid/lymphoid or mixed-lineage leukemia protein 3;
GN   Name=KMT2C; Synonyms=HALR, KIAA1506, MLL3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT PRO-526.
RC   TISSUE=Fetal thymus;
RX   PubMed=11891048; DOI=10.1016/S0378-1119(02)00392-X;
RA   Ruault M., Brun M.-E., Ventura M., Roizes G., De Sario A.;
RT   "MLL3, a new human member of the TRX/MLL gene family, maps to 7q36, a
RT   chromosome region frequently deleted in myeloid leukaemia.";
RL   Gene 284:73-81(2002).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RC   TISSUE=Cervix carcinoma;
RX   PubMed=11718452;
RA   Tan Y.C., Chow V.T.;
RT   "Novel human HALR (MLL3) gene encodes a protein homologous to ALR and
RT   to ALL-1 involved in leukemia, and maps to chromosome 7q36 associated
RT   with leukemia and developmental defects.";
RL   Cancer Detect. Prev. 25:454-469(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12853948; DOI=10.1038/nature01782;
RA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R.,
RA   Wylie K., Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H.,
RA   Sun H., Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A.,
RA   Vanbrunt A., Nguyen C., Du F., Lamar B., Courtney L., Kalicki J.,
RA   Ozersky P., Bielicki L., Scott K., Holmes A., Harkins R., Harris A.,
RA   Strong C.M., Hou S., Tomlinson C., Dauphin-Kohlberg S.,
RA   Kozlowicz-Reilly A., Leonard S., Rohlfing T., Rock S.M.,
RA   Tin-Wollam A.-M., Abbott A., Minx P., Maupin R., Strowmatt C.,
RA   Latreille P., Miller N., Johnson D., Murray J., Woessner J.P.,
RA   Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W., Spieth J.,
RA   Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E., Cook L.L.,
RA   Hickenbotham M.T., Eldred J., Williams D., Bedell J.A., Mardis E.R.,
RA   Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K.,
RA   Simms E., Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S.,
RA   Baertsch R.A., Brent M.R., Keibler E., Flicek P., Bork P., Suyama M.,
RA   Bailey J.A., Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R.,
RA   Eddy S.R., McPherson J.D., Olson M.V., Eichler E.E., Green E.D.,
RA   Waterston R.H., Wilson R.K.;
RT   "The DNA sequence of human chromosome 7.";
RL   Nature 424:157-164(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 556-3865 (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=10819331; DOI=10.1093/dnares/7.2.143;
RA   Nagase T., Kikuno R., Ishikawa K., Hirosawa M., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XVII.
RT   The complete sequences of 100 new cDNA clones from brain which code
RT   for large proteins in vitro.";
RL   DNA Res. 7:143-150(2000).
RN   [5]
RP   SEQUENCE REVISION.
RX   PubMed=12168954; DOI=10.1093/dnares/9.3.99;
RA   Nakajima D., Okazaki N., Yamakawa H., Kikuno R., Ohara O., Nagase T.;
RT   "Construction of expression-ready cDNA clones for KIAA genes: manual
RT   curation of 330 KIAA cDNA clones.";
RL   DNA Res. 9:99-106(2002).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 3193-3865 AND 4460-4911.
RC   TISSUE=Placenta;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [7]
RP   PARTIAL NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3).
RC   TISSUE=Testis;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [8]
RP   INTERACTION WITH MLL2/3 COMPLEX (ISOFORM 2).
RC   TISSUE=Cervix carcinoma;
RX   PubMed=12482968; DOI=10.1128/MCB.23.1.140-149.2003;
RA   Goo Y.-H., Sohn Y.C., Kim D.-H., Kim S.-W., Kang M.-J., Jung D.-J.,
RA   Kwak E., Barlev N.A., Berger S.L., Chow V.T., Roeder R.G.,
RA   Azorsa D.O., Meltzer P.S., Suh P.-G., Song E.J., Lee K.-J., Lee Y.C.,
RA   Lee J.W.;
RT   "Activating signal cointegrator 2 belongs to a novel steady-state
RT   complex that contains a subset of trithorax group proteins.";
RL   Mol. Cell. Biol. 23:140-149(2003).
RN   [9]
RP   IDENTIFICATION IN THE MLL2/3 (ASCOM) COMPLEX.
RX   PubMed=17021013; DOI=10.1073/pnas.0607313103;
RA   Lee S., Lee D.K., Dou Y., Lee J., Lee B., Kwak E., Kong Y.Y.,
RA   Lee S.K., Roeder R.G., Lee J.W.;
RT   "Coactivator as a target gene specificity determinant for histone H3
RT   lysine 4 methyltransferases.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:15392-15397(2006).
RN   [10]
RP   FUNCTION, ENZYME ACTIVITY, IDENTIFICATION BY MASS SPECTROMETRY, AND
RP   IDENTIFICATION IN THE MLL2/3 COMPLEX.
RX   PubMed=17500065; DOI=10.1074/jbc.M701574200;
RA   Cho Y.-W., Hong T., Hong S., Guo H., Yu H., Kim D., Guszczynski T.,
RA   Dressler G.R., Copeland T.D., Kalkum M., Ge K.;
RT   "PTIP associates with MLL3- and MLL4-containing histone H3 lysine 4
RT   methyltransferase complex.";
RL   J. Biol. Chem. 282:20395-20406(2007).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [12]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-758; LYS-1508; LYS-1772;
RP   LYS-2009; LYS-2802; LYS-2809; LYS-2832 AND LYS-3714, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-46, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-89 AND SER-1301, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-28; SER-113; SER-854;
RP   SER-1987; SER-2828 AND SER-4267, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-200; SER-3758; SER-4034
RP   AND SER-4267, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [17]
RP   STRUCTURE BY NMR OF 342-439.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the first and second PHD domain from
RT   myeloid/lymphoid or mixed-lineage leukemia protein 3 homolog.";
RL   Submitted (OCT-2007) to the PDB data bank.
RN   [18]
RP   STRUCTURE BY NMR OF 1624-1713.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the HMG box of human myeloid/lymphoid or mixed-
RT   lineage leukemia protein 3 homolog.";
RL   Submitted (APR-2008) to the PDB data bank.
RN   [19]
RP   VARIANTS [LARGE SCALE ANALYSIS] GLY-347; ASN-400; TRP-478 AND
RP   SER-3698.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
CC   -!- FUNCTION: Histone methyltransferase. Methylates 'Lys-4' of histone
CC       H3. H3 'Lys-4' methylation represents a specific tag for
CC       epigenetic transcriptional activation. Central component of the
CC       MLL2/3 complex, a coactivator complex of nuclear receptors,
CC       involved in transcriptional coactivation. KMT2C/MLL3 may be a
CC       catalytic subunit of this complex. May be involved in
CC       leukemogenesis and developmental disorder.
CC       {ECO:0000269|PubMed:17500065}.
CC   -!- CATALYTIC ACTIVITY: S-adenosyl-L-methionine + L-lysine-[histone] =
CC       S-adenosyl-L-homocysteine + N(6)-methyl-L-lysine-[histone].
CC       {ECO:0000269|PubMed:17500065}.
CC   -!- SUBUNIT: Component of the MLL2/3 complex (also named ASCOM
CC       complex), at least composed of KMT2D/MLL2 or KMT2C/MLL3, ASH2L,
CC       RBBP5, WDR5, NCOA6, DPY30, KDM6A, PAXIP1/PTIP, PAGR1 and alpha-
CC       and beta-tubulin. Interacts with histone H3.
CC       {ECO:0000269|PubMed:17021013, ECO:0000269|PubMed:17500065}.
CC   -!- INTERACTION:
CC       Q14686:NCOA6; NbExp=5; IntAct=EBI-1042997, EBI-78670;
CC       P61964:WDR5; NbExp=4; IntAct=EBI-1042997, EBI-540834;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000305}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q8NEZ4-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q8NEZ4-2; Sequence=VSP_008561, VSP_008562, VSP_036223;
CC         Note=No experimental confirmation available.;
CC       Name=3;
CC         IsoId=Q8NEZ4-3; Sequence=VSP_008562;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Highly expressed in testis and ovary, followed
CC       by brain and liver. Also expressed in placenta, peripherical
CC       blood, fetal thymus, heart, lung and kidney. Within brain,
CC       expression was highest in hippocampus, caudate nucleus, and
CC       substantia nigra. Not detected in skeletal muscle and fetal liver.
CC   -!- DOMAIN: The SET domain interacts with histone H3 but not H2A, H2B
CC       and H4, and may have a H3 lysine specific methylation activity.
CC   -!- MISCELLANEOUS: Found in a critical region of chromosome 7, which
CC       is commonly deleted in malignant myeloid disorders. Partial
CC       duplication of the KMT2C gene are found in the juxtacentromeric
CC       region of chromosomes 1, 2, 13 and 21. Juxtacentromeric
CC       reshuffling of the KMT2C gene has generated the BAGE genes.
CC   -!- SIMILARITY: Belongs to the class V-like SAM-binding
CC       methyltransferase superfamily. Histone-lysine methyltransferase
CC       family. TRX/MLL subfamily. {ECO:0000255|PROSITE-ProRule:PRU00190}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AY024361; AAK00583.1; -; mRNA.
DR   EMBL; AF264750; AAF74766.2; -; mRNA.
DR   EMBL; AC006017; AAD45822.1; -; Genomic_DNA.
DR   EMBL; AC104692; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC005631; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AB040939; BAA96030.2; -; mRNA.
DR   EMBL; AK022687; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; AK075113; BAC11409.1; -; mRNA.
DR   EMBL; AL833924; CAD38780.1; -; mRNA.
DR   CCDS; CCDS5931.1; -. [Q8NEZ4-1]
DR   RefSeq; NP_733751.2; NM_170606.2. [Q8NEZ4-1]
DR   UniGene; Hs.647120; -.
DR   PDB; 2YSM; NMR; -; A=342-439.
DR   PDB; 2YUK; NMR; -; A=1631-1713.
DR   PDB; 3UVL; X-ray; 2.20 A; B=4707-4717.
DR   PDB; 4ERY; X-ray; 1.30 A; D=4703-4716.
DR   PDB; 5F59; X-ray; 2.80 A; A=4757-4910.
DR   PDB; 5F6K; X-ray; 2.41 A; C/E=4757-4911.
DR   PDBsum; 2YSM; -.
DR   PDBsum; 2YUK; -.
DR   PDBsum; 3UVL; -.
DR   PDBsum; 4ERY; -.
DR   PDBsum; 5F59; -.
DR   PDBsum; 5F6K; -.
DR   ProteinModelPortal; Q8NEZ4; -.
DR   SMR; Q8NEZ4; -.
DR   BioGrid; 121835; 24.
DR   DIP; DIP-48649N; -.
DR   IntAct; Q8NEZ4; 18.
DR   MINT; MINT-3042700; -.
DR   STRING; 9606.ENSP00000262189; -.
DR   BindingDB; Q8NEZ4; -.
DR   ChEMBL; CHEMBL2189113; -.
DR   iPTMnet; Q8NEZ4; -.
DR   PhosphoSitePlus; Q8NEZ4; -.
DR   BioMuta; KMT2C; -.
DR   DMDM; 221222521; -.
DR   EPD; Q8NEZ4; -.
DR   MaxQB; Q8NEZ4; -.
DR   PaxDb; Q8NEZ4; -.
DR   PeptideAtlas; Q8NEZ4; -.
DR   PRIDE; Q8NEZ4; -.
DR   Ensembl; ENST00000262189; ENSP00000262189; ENSG00000055609. [Q8NEZ4-1]
DR   Ensembl; ENST00000355193; ENSP00000347325; ENSG00000055609. [Q8NEZ4-1]
DR   GeneID; 58508; -.
DR   KEGG; hsa:58508; -.
DR   UCSC; uc003wla.3; human. [Q8NEZ4-1]
DR   CTD; 58508; -.
DR   DisGeNET; 58508; -.
DR   GeneCards; KMT2C; -.
DR   H-InvDB; HIX0007238; -.
DR   H-InvDB; HIX0016202; -.
DR   H-InvDB; HIX0080234; -.
DR   HGNC; HGNC:13726; KMT2C.
DR   HPA; HPA074736; -.
DR   MIM; 606833; gene.
DR   neXtProt; NX_Q8NEZ4; -.
DR   OpenTargets; ENSG00000055609; -.
DR   PharmGKB; PA30847; -.
DR   eggNOG; KOG4443; Eukaryota.
DR   eggNOG; COG2940; LUCA.
DR   GeneTree; ENSGT00760000119228; -.
DR   HOVERGEN; HBG045586; -.
DR   InParanoid; Q8NEZ4; -.
DR   KO; K09188; -.
DR   OMA; MPSLPGW; -.
DR   OrthoDB; EOG091G000H; -.
DR   PhylomeDB; Q8NEZ4; -.
DR   TreeFam; TF354317; -.
DR   Reactome; R-HSA-3214841; PKMTs methylate histone lysines.
DR   Reactome; R-HSA-5617472; Activation of anterior HOX genes in hindbrain development during early embryogenesis.
DR   EvolutionaryTrace; Q8NEZ4; -.
DR   GeneWiki; MLL3; -.
DR   GenomeRNAi; 58508; -.
DR   PRO; PR:Q8NEZ4; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   Bgee; ENSG00000055609; -.
DR   CleanEx; HS_MLL3; -.
DR   ExpressionAtlas; Q8NEZ4; baseline and differential.
DR   Genevisible; Q8NEZ4; HS.
DR   GO; GO:0035097; C:histone methyltransferase complex; IDA:MGI.
DR   GO; GO:0044666; C:MLL3/4 complex; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:MGI.
DR   GO; GO:0003677; F:DNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0042800; F:histone methyltransferase activity (H3-K4 specific); IDA:MGI.
DR   GO; GO:0018024; F:histone-lysine N-methyltransferase activity; TAS:Reactome.
DR   GO; GO:0003723; F:RNA binding; IDA:UniProtKB.
DR   GO; GO:0016746; F:transferase activity, transferring acyl groups; IEA:UniProtKB-KW.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IEA:UniProtKB-KW.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   Gene3D; 3.30.40.10; -; 6.
DR   InterPro; IPR034732; EPHD.
DR   InterPro; IPR003889; FYrich_C.
DR   InterPro; IPR003888; FYrich_N.
DR   InterPro; IPR009071; HMG_box_dom.
DR   InterPro; IPR000637; HMGI/Y_DNA-bd_CS.
DR   InterPro; IPR003616; Post-SET_dom.
DR   InterPro; IPR001214; SET_dom.
DR   InterPro; IPR011011; Znf_FYVE_PHD.
DR   InterPro; IPR001965; Znf_PHD.
DR   InterPro; IPR019787; Znf_PHD-finger.
DR   InterPro; IPR001841; Znf_RING.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   Pfam; PF05965; FYRC; 1.
DR   Pfam; PF05964; FYRN; 1.
DR   Pfam; PF00628; PHD; 2.
DR   Pfam; PF00856; SET; 1.
DR   SMART; SM00542; FYRC; 1.
DR   SMART; SM00541; FYRN; 1.
DR   SMART; SM00398; HMG; 1.
DR   SMART; SM00249; PHD; 8.
DR   SMART; SM00508; PostSET; 1.
DR   SMART; SM00184; RING; 4.
DR   SMART; SM00317; SET; 1.
DR   SUPFAM; SSF47095; SSF47095; 1.
DR   SUPFAM; SSF57903; SSF57903; 6.
DR   PROSITE; PS50216; DHHC; 1.
DR   PROSITE; PS51805; EPHD; 2.
DR   PROSITE; PS51543; FYRC; 1.
DR   PROSITE; PS51542; FYRN; 1.
DR   PROSITE; PS00354; HMGI_Y; 1.
DR   PROSITE; PS50868; POST_SET; 1.
DR   PROSITE; PS50280; SET; 1.
DR   PROSITE; PS01359; ZF_PHD_1; 5.
DR   PROSITE; PS50016; ZF_PHD_2; 6.
DR   PROSITE; PS50089; ZF_RING_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Activator; Acyltransferase;
KW   Alternative splicing; Chromatin regulator; Coiled coil;
KW   Complete proteome; DNA-binding; Lipoprotein; Metal-binding;
KW   Methylation; Methyltransferase; Nucleus; Palmitate; Phosphoprotein;
KW   Polymorphism; Reference proteome; Repeat; S-adenosyl-L-methionine;
KW   Transcription; Transcription regulation; Transferase; Zinc;
KW   Zinc-finger.
FT   CHAIN         1   4911       Histone-lysine N-methyltransferase 2C.
FT                                /FTId=PRO_0000124879.
FT   DOMAIN      436    489       DHHC. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00067}.
FT   DOMAIN     4545   4605       FYR N-terminal. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00875}.
FT   DOMAIN     4606   4691       FYR C-terminal. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00876}.
FT   DOMAIN     4771   4887       SET. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00190}.
FT   DOMAIN     4895   4911       Post-SET. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00155}.
FT   DNA_BIND     34     46       A.T hook.
FT   ZN_FING     227    262       C2HC pre-PHD-type 1; degenerate.
FT                                {ECO:0000255|PROSITE-ProRule:PRU01146}.
FT   ZN_FING     283    331       PHD-type 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU01146}.
FT   ZN_FING     341    391       PHD-type 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00146}.
FT   ZN_FING     344    389       RING-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00175}.
FT   ZN_FING     388    438       PHD-type 3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00146}.
FT   ZN_FING     464    520       PHD-type 4. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00146}.
FT   ZN_FING     957   1010       PHD-type 5. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00146}.
FT   ZN_FING    1007   1057       PHD-type 6. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00146}.
FT   ZN_FING    1084   1139       PHD-type 7. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00146}.
FT   ZN_FING    4399   4439       C2HC pre-PHD-type 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU01146}.
FT   ZN_FING    4460   4507       PHD-type 8. {ECO:0000255|PROSITE-
FT                                ProRule:PRU01146}.
FT   REGION     4848   4849       S-adenosyl-L-methionine binding.
FT                                {ECO:0000250}.
FT   COILED       92    112       {ECO:0000255}.
FT   COILED      644    672       {ECO:0000255}.
FT   COILED     1338   1366       {ECO:0000255}.
FT   COILED     1754   1787       {ECO:0000255}.
FT   COILED     3054   3081       {ECO:0000255}.
FT   COILED     3173   3272       {ECO:0000255}.
FT   COILED     3391   3433       {ECO:0000255}.
FT   COMPBIAS   1719   1796       Gln-rich.
FT   COMPBIAS   1834   2281       Pro-rich.
FT   COMPBIAS   2412   2630       Pro-rich.
FT   COMPBIAS   2690   2786       Asp-rich.
FT   COMPBIAS   3012   3509       Gln-rich.
FT   COMPBIAS   3277   3381       Pro-rich.
FT   METAL      4851   4851       Zinc. {ECO:0000250}.
FT   METAL      4899   4899       Zinc. {ECO:0000250}.
FT   METAL      4901   4901       Zinc. {ECO:0000250}.
FT   METAL      4906   4906       Zinc. {ECO:0000250}.
FT   BINDING    4825   4825       S-adenosyl-L-methionine.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00190}.
FT   MOD_RES      28     28       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES      46     46       Phosphoserine.
FT                                {ECO:0000244|PubMed:20068231}.
FT   MOD_RES      89     89       Phosphoserine.
FT                                {ECO:0000244|PubMed:21406692}.
FT   MOD_RES     113    113       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     200    200       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     758    758       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     854    854       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1301   1301       Phosphoserine.
FT                                {ECO:0000244|PubMed:21406692}.
FT   MOD_RES    1508   1508       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES    1772   1772       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES    1987   1987       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    2009   2009       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES    2454   2454       Asymmetric dimethylarginine.
FT                                {ECO:0000250|UniProtKB:Q8BRH4}.
FT   MOD_RES    2571   2571       Asymmetric dimethylarginine.
FT                                {ECO:0000250|UniProtKB:Q8BRH4}.
FT   MOD_RES    2802   2802       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES    2809   2809       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES    2828   2828       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    2832   2832       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES    2867   2867       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:Q8BRH4}.
FT   MOD_RES    3714   3714       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES    3758   3758       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES    4034   4034       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES    4139   4139       Asymmetric dimethylarginine.
FT                                {ECO:0000250|UniProtKB:Q8BRH4}.
FT   MOD_RES    4267   4267       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   VAR_SEQ       1    939       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:11718452}.
FT                                /FTId=VSP_008561.
FT   VAR_SEQ    3890   3890       Q -> QVRQLSLLPLMEPIIGVNFAHFLPYGSGQFNSGNRL
FT                                LGTFGSATLEGVSDYYSQLIYK (in isoform 2 and
FT                                isoform 3).
FT                                {ECO:0000303|PubMed:11718452}.
FT                                /FTId=VSP_008562.
FT   VAR_SEQ    4721   4724       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:11718452}.
FT                                /FTId=VSP_036223.
FT   VARIANT     291    291       L -> F (in dbSNP:rs56850341).
FT                                /FTId=VAR_061911.
FT   VARIANT     316    316       T -> S (in dbSNP:rs10454320).
FT                                /FTId=VAR_061912.
FT   VARIANT     347    347       C -> G (in a colorectal cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_036311.
FT   VARIANT     400    400       D -> N (in a colorectal cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_036312.
FT   VARIANT     478    478       L -> W (in a colorectal cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_036313.
FT   VARIANT     526    526       R -> P (in dbSNP:rs3735156).
FT                                {ECO:0000269|PubMed:11891048}.
FT                                /FTId=VAR_057360.
FT   VARIANT     823    823       I -> N (in dbSNP:rs2838171).
FT                                /FTId=VAR_017118.
FT   VARIANT     823    823       I -> T (in dbSNP:rs2838171).
FT                                /FTId=VAR_017117.
FT   VARIANT    1836   1836       S -> N (in dbSNP:rs11771635).
FT                                /FTId=VAR_057361.
FT   VARIANT    2008   2008       T -> A (in dbSNP:rs6951159).
FT                                /FTId=VAR_057362.
FT   VARIANT    2412   2412       P -> T (in dbSNP:rs13231116).
FT                                /FTId=VAR_057363.
FT   VARIANT    2600   2600       P -> A (in dbSNP:rs2270234).
FT                                /FTId=VAR_057364.
FT   VARIANT    3698   3698       T -> S (in a colorectal cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_036314.
FT   CONFLICT    579    579       A -> T (in Ref. 1; AAK00583).
FT                                {ECO:0000305}.
FT   CONFLICT   1286   1286       M -> V (in Ref. 1; AAK00583).
FT                                {ECO:0000305}.
FT   CONFLICT   2360   2360       P -> S (in Ref. 1; AAK00583).
FT                                {ECO:0000305}.
FT   CONFLICT   2797   2797       K -> R (in Ref. 1; AAK00583).
FT                                {ECO:0000305}.
FT   CONFLICT   2882   2882       T -> A (in Ref. 1; AAK00583).
FT                                {ECO:0000305}.
FT   CONFLICT   3289   3289       P -> S (in Ref. 6; BAC11409).
FT                                {ECO:0000305}.
FT   CONFLICT   3428   3428       R -> W (in Ref. 6; BAC11409).
FT                                {ECO:0000305}.
FT   CONFLICT   4613   4613       I -> V (in Ref. 6; AK022687).
FT                                {ECO:0000305}.
FT   CONFLICT   4866   4866       H -> P (in Ref. 6; AK022687).
FT                                {ECO:0000305}.
FT   TURN        345    347       {ECO:0000244|PDB:2YSM}.
FT   TURN        353    355       {ECO:0000244|PDB:2YSM}.
FT   STRAND      356    358       {ECO:0000244|PDB:2YSM}.
FT   STRAND      360    362       {ECO:0000244|PDB:2YSM}.
FT   TURN        368    372       {ECO:0000244|PDB:2YSM}.
FT   TURN        377    379       {ECO:0000244|PDB:2YSM}.
FT   TURN        386    388       {ECO:0000244|PDB:2YSM}.
FT   TURN        392    394       {ECO:0000244|PDB:2YSM}.
FT   STRAND      403    405       {ECO:0000244|PDB:2YSM}.
FT   STRAND      407    409       {ECO:0000244|PDB:2YSM}.
FT   STRAND      412    414       {ECO:0000244|PDB:2YSM}.
FT   HELIX       415    417       {ECO:0000244|PDB:2YSM}.
FT   STRAND      418    420       {ECO:0000244|PDB:2YSM}.
FT   HELIX       433    436       {ECO:0000244|PDB:2YSM}.
FT   HELIX      1636   1645       {ECO:0000244|PDB:2YUK}.
FT   HELIX      1646   1648       {ECO:0000244|PDB:2YUK}.
FT   STRAND     1650   1652       {ECO:0000244|PDB:2YUK}.
FT   HELIX      1653   1660       {ECO:0000244|PDB:2YUK}.
FT   HELIX      1664   1667       {ECO:0000244|PDB:2YUK}.
FT   HELIX      1671   1684       {ECO:0000244|PDB:2YUK}.
FT   HELIX      1687   1706       {ECO:0000244|PDB:2YUK}.
FT   STRAND     4707   4709       {ECO:0000244|PDB:4ERY}.
FT   HELIX      4758   4768       {ECO:0000244|PDB:5F6K}.
FT   HELIX      4769   4771       {ECO:0000244|PDB:5F6K}.
FT   STRAND     4773   4777       {ECO:0000244|PDB:5F6K}.
FT   STRAND     4779   4789       {ECO:0000244|PDB:5F6K}.
FT   STRAND     4796   4800       {ECO:0000244|PDB:5F6K}.
FT   STRAND     4802   4806       {ECO:0000244|PDB:5F6K}.
FT   HELIX      4807   4817       {ECO:0000244|PDB:5F6K}.
FT   TURN       4818   4821       {ECO:0000244|PDB:5F6K}.
FT   STRAND     4826   4828       {ECO:0000244|PDB:5F6K}.
FT   STRAND     4830   4841       {ECO:0000244|PDB:5F6K}.
FT   HELIX      4843   4846       {ECO:0000244|PDB:5F6K}.
FT   STRAND     4854   4862       {ECO:0000244|PDB:5F6K}.
FT   STRAND     4865   4874       {ECO:0000244|PDB:5F6K}.
FT   STRAND     4908   4910       {ECO:0000244|PDB:5F59}.
SQ   SEQUENCE   4911 AA;  541370 MW;  898CEE324772BD75 CRC64;
     MSSEEDKSVE QPQPPPPPPE EPGAPAPSPA AADKRPRGRP RKDGASPFQR ARKKPRSRGK
     TAVEDEDSMD GLETTETETI VETEIKEQSA EEDAEAEVDN SKQLIPTLQR SVSEESANSL
     VSVGVEAKIS EQLCAFCYCG EKSSLGQGDL KQFRITPGFI LPWRNQPSNK KDIDDNSNGT
     YEKMQNSAPR KQRGQRKERS PQQNIVSCVS VSTQTASDDQ AGKLWDELSL VGLPDAIDIQ
     ALFDSTGTCW AHHRCVEWSL GVCQMEEPLL VNVDKAVVSG STERCAFCKH LGATIKCCEE
     KCTQMYHYPC AAGAGTFQDF SHIFLLCPEH IDQAPERSKE DANCAVCDSP GDLLDQFFCT
     TCGQHYHGMC LDIAVTPLKR AGWQCPECKV CQNCKQSGED SKMLVCDTCD KGYHTFCLQP
     VMKSVPTNGW KCKNCRICIE CGTRSSSQWH HNCLICDNCY QQQDNLCPFC GKCYHPELQK
     DMLHCNMCKR WVHLECDKPT DHELDTQLKE EYICMYCKHL GAEMDRLQPG EEVEIAELTT
     DYNNEMEVEG PEDQMVFSEQ AANKDVNGQE STPGIVPDAV QVHTEEQQKS HPSESLDTDS
     LLIAVSSQHT VNTELEKQIS NEVDSEDLKM SSEVKHICGE DQIEDKMEVT ENIEVVTHQI
     TVQQEQLQLL EEPETVVSRE ESRPPKLVME SVTLPLETLV SPHEESISLC PEEQLVIERL
     QGEKEQKENS ELSTGLMDSE MTPTIEGCVK DVSYQGGKSI KLSSETESSF SSSADISKAD
     VSSSPTPSSD LPSHDMLHNY PSALSSSAGN IMPTTYISVT PKIGMGKPAI TKRKFSPGRP
     RSKQGAWSTH NTVSPPSWSP DISEGREIFK PRQLPGSAIW SIKVGRGSGF PGKRRPRGAG
     LSGRGGRGRS KLKSGIGAVV LPGVSTADIS SNKDDEENSM HNTVVLFSSS DKFTLNQDMC
     VVCGSFGQGA EGRLLACSQC GQCYHPYCVS IKITKVVLSK GWRCLECTVC EACGKATDPG
     RLLLCDDCDI SYHTYCLDPP LQTVPKGGWK CKWCVWCRHC GATSAGLRCE WQNNYTQCAP
     CASLSSCPVC YRNYREEDLI LQCRQCDRWM HAVCQNLNTE EEVENVADIG FDCSMCRPYM
     PASNVPSSDC CESSLVAQIV TKVKELDPPK TYTQDGVCLT ESGMTQLQSL TVTVPRRKRS
     KPKLKLKIIN QNSVAVLQTP PDIQSEHSRD GEMDDSREGE LMDCDGKSES SPEREAVDDE
     TKGVEGTDGV KKRKRKPYRP GIGGFMVRQR SRTGQGKTKR SVIRKDSSGS ISEQLPCRDD
     GWSEQLPDTL VDESVSVTES TEKIKKRYRK RKNKLEETFP AYLQEAFFGK DLLDTSRQSK
     ISLDNLSEDG AQLLYKTNMN TGFLDPSLDP LLSSSSAPTK SGTHGPADDP LADISEVLNT
     DDDILGIISD DLAKSVDHSD IGPVTDDPSS LPQPNVNQSS RPLSEEQLDG ILSPELDKMV
     TDGAILGKLY KIPELGGKDV EDLFTAVLSP ANTQPTPLPQ PPPPTQLLPI HNQDAFSRMP
     LMNGLIGSSP HLPHNSLPPG SGLGTFSAIA QSSYPDARDK NSAFNPMASD PNNSWTSSAP
     TVEGENDTMS NAQRSTLKWE KEEALGEMAT VAPVLYTNIN FPNLKEEFPD WTTRVKQIAK
     LWRKASSQER APYVQKARDN RAALRINKVQ MSNDSMKRQQ QQDSIDPSSR IDSELFKDPL
     KQRESEHEQE WKFRQQMRQK SKQQAKIEAT QKLEQVKNEQ QQQQQQQFGS QHLLVQSGSD
     TPSSGIQSPL TPQPGNGNMS PAQSFHKELF TKQPPSTPTS TSSDDVFVKP QAPPPPPAPS
     RIPIQDSLSQ AQTSQPPSPQ VFSPGSSNSR PPSPMDPYAK MVGTPRPPPV GHSFSRRNSA
     APVENCTPLS SVSRPLQMNE TTANRPSPVR DLCSSSTTNN DPYAKPPDTP RPVMTDQFPK
     SLGLSRSPVV SEQTAKGPIA AGTSDHFTKP SPRADVFQRQ RIPDSYARPL LTPAPLDSGP
     GPFKTPMQPP PSSQDPYGSV SQASRRLSVD PYERPALTPR PIDNFSHNQS NDPYSQPPLT
     PHPAVNESFA HPSRAFSQPG TISRPTSQDP YSQPPGTPRP VVDSYSQSSG TARSNTDPYS
     QPPGTPRPTT VDPYSQQPQT PRPSTQTDLF VTPVTNQRHS DPYAHPPGTP RPGISVPYSQ
     PPATPRPRIS EGFTRSSMTR PVLMPNQDPF LQAAQNRGPA LPGPLVRPPD TCSQTPRPPG
     PGLSDTFSRV SPSAARDPYD QSPMTPRSQS DSFGTSQTAH DVADQPRPGS EGSFCASSNS
     PMHSQGQQFS GVSQLPGPVP TSGVTDTQNT VNMAQADTEK LRQRQKLREI ILQQQQQKKI
     AGRQEKGSQD SPAVPHPGPL QHWQPENVNQ AFTRPPPPYP GNIRSPVAPP LGPRYAVFPK
     DQRGPYPPDV ASMGMRPHGF RFGFPGGSHG TMPSQERFLV PPQQIQGSGV SPQLRRSVSV
     DMPRPLNNSQ MNNPVGLPQH FSPQSLPVQQ HNILGQAYIE LRHRAPDGRQ RLPFSAPPGS
     VVEASSNLRH GNFIPRPDFP GPRHTDPMRR PPQGLPNQLP VHPDLEQVPP SQQEQGHSVH
     SSSMVMRTLN HPLGGEFSEA PLSTSVPSET TSDNLQITTQ PSDGLEEKLD SDDPSVKELD
     VKDLEGVEVK DLDDEDLENL NLDTEDGKVV ELDTLDNLET NDPNLDDLLR SGEFDIIAYT
     DPELDMGDKK SMFNEELDLP IDDKLDNQCV SVEPKKKEQE NKTLVLSDKH SPQKKSTVTN
     EVKTEVLSPN SKVESKCETE KNDENKDNVD TPCSQASAHS DLNDGEKTSL HPCDPDLFEK
     RTNRETAGPS ANVIQASTQL PAQDVINSCG ITGSTPVLSS LLANEKSDNS DIRPSGSPPP
     PTLPASPSNH VSSLPPFIAP PGRVLDNAMN SNVTVVSRVN HVFSQGVQVN PGLIPGQSTV
     NHSLGTGKPA TQTGPQTSQS GTSSMSGPQQ LMIPQTLAQQ NRERPLLLEE QPLLLQDLLD
     QERQEQQQQR QMQAMIRQRS EPFFPNIDFD AITDPIMKAK MVALKGINKV MAQNNLGMPP
     MVMSRFPFMG QVVTGTQNSE GQNLGPQAIP QDGSITHQIS RPNPPNFGPG FVNDSQRKQY
     EEWLQETQQL LQMQQKYLEE QIGAHRKSKK ALSAKQRTAK KAGREFPEED AEQLKHVTEQ
     QSMVQKQLEQ IRKQQKEHAE LIEDYRIKQQ QQCAMAPPTM MPSVQPQPPL IPGATPPTMS
     QPTFPMVPQQ LQHQQHTTVI SGHTSPVRMP SLPGWQPNSA PAHLPLNPPR IQPPIAQLPI
     KTCTPAPGTV SNANPQSGPP PRVEFDDNNP FSESFQERER KERLREQQER QRIQLMQEVD
     RQRALQQRME MEQHGMVGSE ISSSRTSVSQ IPFYSSDLPC DFMQPLGPLQ QSPQHQQQMG
     QVLQQQNIQQ GSINSPSTQT FMQTNERRQV GPPSFVPDSP SIPVGSPNFS SVKQGHGNLS
     GTSFQQSPVR PSFTPALPAA PPVANSSLPC GQDSTITHGH SYPGSTQSLI QLYSDIIPEE
     KGKKKRTRKK KRDDDAESTK APSTPHSDIT APPTPGISET TSTPAVSTPS ELPQQADQES
     VEPVGPSTPN MAAGQLCTEL ENKLPNSDFS QATPNQQTYA NSEVDKLSME TPAKTEEIKL
     EKAETESCPG QEEPKLEEQN GSKVEGNAVA CPVSSAQSPP HSAGAPAAKG DSGNELLKHL
     LKNKKSSSLL NQKPEGSICS EDDCTKDNKL VEKQNPAEGL QTLGAQMQGG FGCGNQLPKT
     DGGSETKKQR SKRTQRTGEK AAPRSKKRKK DEEEKQAMYS STDTFTHLKQ QNNLSNPPTP
     PASLPPTPPP MACQKMANGF ATTEELAGKA GVLVSHEVTK TLGPKPFQLP FRPQDDLLAR
     ALAQGPKTVD VPASLPTPPH NNQEELRIQD HCGDRDTPDS FVPSSSPESV VGVEVSRYPD
     LSLVKEEPPE PVPSPIIPIL PSTAGKSSES RRNDIKTEPG TLYFASPFGP SPNGPRSGLI
     SVAITLHPTA AENISSVVAA FSDLLHVRIP NSYEVSSAPD VPSMGLVSSH RINPGLEYRQ
     HLLLRGPPPG SANPPRLVSS YRLKQPNVPF PPTSNGLSGY KDSSHGIAES AALRPQWCCH
     CKVVILGSGV RKSFKDLTLL NKDSRESTKR VEKDIVFCSN NCFILYSSTA QAKNSENKES
     IPSLPQSPMR ETPSKAFHQY SNNISTLDVH CLPQLPEKAS PPASPPIAFP PAFEAAQVEA
     KPDELKVTVK LKPRLRAVHG GFEDCRPLNK KWRGMKWKKW SIHIVIPKGT FKPPCEDEID
     EFLKKLGTSL KPDPVPKDYR KCCFCHEEGD GLTDGPARLL NLDLDLWVHL NCALWSTEVY
     ETQAGALINV ELALRRGLQM KCVFCHKTGA TSGCHRFRCT NIYHFTCAIK AQCMFFKDKT
     MLCPMHKPKG IHEQELSYFA VFRRVYVQRD EVRQIASIVQ RGERDHTFRV GSLIFHTIGQ
     LLPQQMQAFH SPKALFPVGY EASRLYWSTR YANRRCRYLC SIEEKDGRPV FVIRIVEQGH
     EDLVLSDISP KGVWDKILEP VACVRKKSEM LQLFPAYLKG EDLFGLTVSA VARIAESLPG
     VEACENYTFR YGRNPLMELP LAVNPTGCAR SEPKMSAHVK RFVLRPHTLN STSTSKSFQS
     TVTGELNAPY SKQFVHSKSS QYRKMKTEWK SNVYLARSRI QGLGLYAARD IEKHTMVIEY
     IGTIIRNEVA NRKEKLYESQ NRGVYMFRMD NDHVIDATLT GGPARYINHS CAPNCVAEVV
     TFERGHKIII SSSRRIQKGE ELCYDYKFDF EDDQHKIPCH CGAVNCRKWM N
//
